NCT06364267View on ClinicalTrials.gov

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen 10 MG

Blinded tamoxifen 10 mg every other day

DRUG

Exemestane 25 MG

Blinded exemestane 25 mg every other day

Trial Locations (1)

16128

E.O. Ospedali Galliera, Genova

Sponsors
All Listed Sponsors
collaborator

Dana-Farber/Brigham and Women's Cancer Center

OTHER

collaborator

Herbert Irving Comprehensive Cancer Center

OTHER

collaborator

Istituto Europeo di Oncologia

OTHER

collaborator

Breast Cancer Research Foundation

OTHER

lead

Andrea DeCensi

OTHER